Vybion

Vybion is a private, preclinical-stage biotech focused on a novel intrabody platform for neurodegenerative diseases. The company's core technology involves engineering scFv antibody fragments that can be delivered inside cells using AAV or exosomal vectors to interfere with intracellular pathogenic mechanisms. With Orphan Drug Designation for its lead candidate INT41 in Huntington's disease and a pre-IND meeting completed, Vybion is advancing towards clinical development. The leadership team combines deep experience in biologics development, gene therapy, regulatory strategy, and corporate finance.

Vectorized Intrabody platform using engineered single-chain variable fragment (scFv) antibodies delivered intracellularly via AAV or exosomal vectors to target protein aggregation, gene dysregulation, and toxic protein turnover.

Vybion competes in the Huntington's disease space against companies developing antisense oligonucleotides (e.g., Roche/Ionis), RNA interference therapies, and other gene-targeting approaches. Its differentiation lies in the intrabody mechanism, which aims to alter the function or fate of the toxic protein fragment rather than simply reducing its production, a potentially complementary or superior strategy.